Immunic AG · ISIN: US4525EP1011 · EQS - Company News

Immunic, Inc. to Participate in Investor Conference in December

Immunic, Inc. to Participate in Investor Conference in December  NEW YORK, November 26, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Thursday, December 5, 2024, at 11:30 am ET, during the Piper Sandler 36th Annual Healthcare Conference, ...

NASDAQ:IMUX Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Immunic AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
26 November 2024 12:30PM
Immunic, Inc. to Participate in Investor Conference in December
US4525EP1011
Immunic, Inc. to Participate in Investor Conference in December  NEW YORK, November 26, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Im...
Immunic AG
About the publication
13 November 2024 12:30PM
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
US4525EP1011
 Immunic Announces Publication of Data From Phase 1/1b  Clinical Trial of IMU-856 in the Peer Reviewed Journal,  The Lancet Gastroenterology & Hepatology  – Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK, November 13, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developi...
Immunic AG
About the publication
07 November 2024 12:30PM
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
US4525EP1011
Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –  – Ongoing, Twin Phase 3 ENSURE Trials ...
Immunic AG
About the publication
31 October 2024 11:30AM
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
US4525EP1011
Immunic, Inc. to Announce Financial Results for the Third Quarter EndedSeptember 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, October 31, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chro...
Immunic AG
About the publication
29 October 2024 11:30AM
Immunic to Participate in Industry, Scientific and Investor Conferences in November
US4525EP1011
Immunic to Participate in Industry, Scientific and Investor Conferences in November NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following indus...
Immunic AG
About the publication
22 October 2024 12:30PM
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
US4525EP1011
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis  – Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met –  – IDMC Also Recommended Continuing Trial without Change...
Immunic AG
About the publication
18 September 2024 12:30PM
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
US4525EP1011
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis – Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P...
Immunic AG
About the publication
18 September 2024 12:30PM
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
US4525EP1011
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis – Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All P...
Immunic AG
About the publication
04 September 2024 12:30PM
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
US4525EP1011
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome  – Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID Rea...
Immunic AG
About the publication
28 August 2024 12:30PM
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
US4525EP1011
Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September NEW YORK, August 28, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that t...
Immunic AG
About the publication
08 August 2024 12:30PM
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
US4525EP1011
 Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President –  – Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceuti...
Immunic AG
About the publication
01 August 2024 12:30PM
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
US4525EP1011
Immunic, Inc. to Announce Financial Results for the Second Quarter EndedJune 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, August 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic infl...
Immunic AG
About the publication
24 July 2024 12:30PM
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
US4525EP1011
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec  – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience –  – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Scl...
Immunic AG
About the publication
More Immunic AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN